- It is already established that a high Oncotype DX recurrence score (RS) predicts distant breast cancer (BCa) recurrence and benefit from adjuvant chemotherapy (ACT) in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early BCa.
- In this cohort study, high RS may also predict benefit from neoadjuvant chemotherapy (NACT).
Why this matters
- First study to support Oncotype DX testing to identify patients most suited for neoadjuvant chemotherapy.
- Retrospective cohort (n=989 patients with T1-T3 ER+/HER2− BCa with RS and receipt of NACT) from the National Cancer Database.
- RS was classified as low (30).
- Funding: None disclosed.
- 23.0% of cohort had low RS, 45.5% had intermediate RS, 31.5% had high RS.
- Pathologic complete response (pCR) after NACT was attained by 4.3% of the cohort.
- pCR after NACT was attained by 9.6% of patients with high RS and 1.6% of patients with intermediate RS.
- High RS (vs intermediate RS) was associated with nearly 5 times the likelihood of achieving pCR after NACT (OR, 4.87; 95% CI, 2.01-11.82) in multivariate analysis.
- Low RS (vs intermediate RS) was not associated with pCR.
- Retrospective, observational design.
- Potential for unmeasured confounders.